 |
인쇄하기
취소
|
Yuhan Corp. introduces novel hepatitis C product
Yuhan Corp. said on July 12 that it has launched in Korea PegIntron (peginterferon alfa-2b), Schering-Plough's novel pegylated interferon product for the treatment of chronic hepatitis C.
A distinct and major characteristic of hepatitis C is its tendency to cause chronic liver disease. At least 80 percent of patients with acute hepatitis C ultimately develop chronic infection, and most of th...
A distinct and major characteristic of hepatitis C is its tendency to cause chronic liver disease. At least 80 percent of patients with acute hepatitis C ultimately develop chronic infection, and most of th...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.